Home >> BML-277
Related Products
BML-277 Chk2 inhibitor,potent and highly selective

Catalog No.B1236
Size Price Stock Qty
10mM (in 1mL DMSO)
$88.00
In stock
10mg
$76.00
In stock
50mg
$304.00
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

      

Sample solution is provided at 25 µL, 10mM.

Quality Control

Chemical structure

BML-277

Protocol

Kinase experiment [1]:

Inhibition of purified chk2

Activity of chk2 inhibitor was determined by incubating BML-277 with recombinant full-length chk2: 5 nM recombinant human Chk2, 50 mM HEPES (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 25 μM synthetic peptide substrate (biotin-SGLYRSPSMPENLNRPR), 1 μM ATP, 50 μCi/mL [γ-33P] ATP and a protease inhibitor mixture. The reaction mixtures were incubated at 37 °C for 3 hrs, and the peptide substrate was captured on streptavidin conjugated to agarose beads. The agarose beads were washed repeatedly with a 0.1% solution of Tween-20 in phosphate-buffered saline, pH 7.4. Enzyme activity at different BML-277 concentrations was determined by measuring the amount of radioactive phosphate bound to the substrate peptide by scintillation counting. In the kinetic experiment, ATP concentration was varied while the ratio between unlabeled and [γ-33P] labeled ATP was kept constant. Reactions were stopped at different time points by addition of 50 mM cold ATP and samples were kept on ice during further processing.

Cell experiment [1]:

Cell lines

Human T-cells

Preparation method

The solubility of this compound in DMSO is > 18.2 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months.

Reacting condition

25 hrs

Applications

BML-277 efficiently prevented T-cell populations from radiation-induced apoptosis in a concentration-dependent manner, with the EC50 value ranging from 3 to 7.6 μM.

References:

[1]. Arienti KL1, Brunmark A, Axe FU, McClure K, Lee A, Blevitt J, Neff DK, Huang L, Crawford S, Pandit CR, Karlsson L, Breitenbucher JG. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem. 2005 Mar 24;48(6):1873-85.

BML-277 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

BML-277 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Chemical Properties

Cas No. 516480-79-8 SDF Download SDF
Chemical Name 2-[4-(4-chlorophenoxy)phenyl]-3H-benzimidazole-5-carboxamide
Canonical SMILES C1=CC(=CC=C1C2=NC3=C(N2)C=C(C=C3)C(=O)N)OC4=CC=C(C=C4)Cl
Formula C20H14ClN3O2 M.Wt 363.8
Solubility >18.2mg/mL in DMSO Storage Store at -20°C
Shipping Condition Evaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

Background

BML-277 is novel, potent and highly selective inhibitor of the chk2 with the IC50 value of 15±6.9nM [1].

BML-277 has shown the ATP-competitive inhibition of chk2 with the Ki value of 37nM. BML-277 has also been exhibited to be a chk2 inhibitor with the IC50 value of 15±6.9nM and efficiently rescue T-cell populations from the apoptosis of radiation-induced in a concentration-dependent fashion with the EC50 of 3~7.6μM. The Km of ATP for chk2 is 99μM and assuming that intracellular ATP concentration is 10mM. Apart from these, BML-277 has shown the inhibition through docking into a homology model of chk2 ATP binging site [1].

References:
[1]Arienti KL1, Brunmark A, Axe FU, McClure K, Lee A, Blevitt J, Neff DK, Huang L, Crawford S, Pandit CR, Karlsson L, Breitenbucher JG. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem. 2005 Mar 24;48(6):1873-85.